• Je něco špatně v tomto záznamu ?

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

IW. Flinn, CB. Miller, KM. Ardeshna, S. Tetreault, SE. Assouline, J. Mayer, M. Merli, SD. Lunin, AR. Pettitt, Z. Nagy, O. Tournilhac, KE. Abou-Nassar, M. Crump, ED. Jacobsen, S. de Vos, VM. Kelly, W. Shi, L. Steelman, N. Le, DT. Weaver, S....

. 2019 ; 37 (11) : 912-922. [pub] 20190211

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006602

PURPOSE: Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies. On the basis of the activity of duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-δ,-γ, in RR iNHL in a phase I study, the safety and efficacy of duvelisib monotherapy was evaluated in iNHL refractory to rituximab and either chemotherapy or radioimmunotherapy. PATIENTS AND METHODS: Eligible patients had measurable iNHL (FL, SLL, or marginal zone B-cell lymphoma) double refractory to rituximab (monotherapy or in combination) and to either chemotherapy or radioimmunotherapy. All were treated with duvelisib 25 mg orally twice daily in 28-day cycles until progression, unacceptable toxicity, or death. The primary end point was overall response rate (ORR) using the revised International Working Group criteria for malignant lymphoma. RESULTS: This open-label, global phase II trial enrolled 129 patients (median age, 65 years; median of three prior lines of therapy) with an ORR of 47.3% (SLL, 67.9%; FL, 42.2%; MZL, 38.9%). The estimated median duration of response was 10 months, and the estimated median progression-free survival was 9.5 months. The most frequent any-grade treatment-emergent adverse events (TEAEs) were diarrhea (48.8%), nausea (29.5%), neutropenia (28.7%), fatigue (27.9%), and cough (27.1%). Among the 88.4% of patients with at least one grade 3 or greater TEAE, the most common TEAEs were neutropenia (24.8%), diarrhea (14.7%), anemia (14.7%), and thrombocytopenia (11.6%). CONCLUSION: In the DYNAMO study, oral duvelisib monotherapy demonstrated clinically meaningful activity and a manageable safety profile in heavily pretreated, double-refractory iNHL, consistent with previous observations. Duvelisib may provide a new oral treatment option for this patient population of which many are elderly and in need of additional therapies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006602
003      
CZ-PrNML
005      
20240313110209.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.18.00915 $2 doi
035    __
$a (PubMed)30742566
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Flinn, Ian W $u Sarah Cannon Research Institute, Nashville, TN. 2 Tennessee Oncology, Nashville, TN.
245    10
$a DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma / $c IW. Flinn, CB. Miller, KM. Ardeshna, S. Tetreault, SE. Assouline, J. Mayer, M. Merli, SD. Lunin, AR. Pettitt, Z. Nagy, O. Tournilhac, KE. Abou-Nassar, M. Crump, ED. Jacobsen, S. de Vos, VM. Kelly, W. Shi, L. Steelman, N. Le, DT. Weaver, S. Lustgarten, ND. Wagner-Johnston, PL. Zinzani,
520    9_
$a PURPOSE: Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies. On the basis of the activity of duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-δ,-γ, in RR iNHL in a phase I study, the safety and efficacy of duvelisib monotherapy was evaluated in iNHL refractory to rituximab and either chemotherapy or radioimmunotherapy. PATIENTS AND METHODS: Eligible patients had measurable iNHL (FL, SLL, or marginal zone B-cell lymphoma) double refractory to rituximab (monotherapy or in combination) and to either chemotherapy or radioimmunotherapy. All were treated with duvelisib 25 mg orally twice daily in 28-day cycles until progression, unacceptable toxicity, or death. The primary end point was overall response rate (ORR) using the revised International Working Group criteria for malignant lymphoma. RESULTS: This open-label, global phase II trial enrolled 129 patients (median age, 65 years; median of three prior lines of therapy) with an ORR of 47.3% (SLL, 67.9%; FL, 42.2%; MZL, 38.9%). The estimated median duration of response was 10 months, and the estimated median progression-free survival was 9.5 months. The most frequent any-grade treatment-emergent adverse events (TEAEs) were diarrhea (48.8%), nausea (29.5%), neutropenia (28.7%), fatigue (27.9%), and cough (27.1%). Among the 88.4% of patients with at least one grade 3 or greater TEAE, the most common TEAEs were neutropenia (24.8%), diarrhea (14.7%), anemia (14.7%), and thrombocytopenia (11.6%). CONCLUSION: In the DYNAMO study, oral duvelisib monotherapy demonstrated clinically meaningful activity and a manageable safety profile in heavily pretreated, double-refractory iNHL, consistent with previous observations. Duvelisib may provide a new oral treatment option for this patient population of which many are elderly and in need of additional therapies.
650    _2
$a aplikace orální $7 D000284
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antiflogistika nesteroidní $x škodlivé účinky $x terapeutické užití $7 D000894
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a průjem $x chemicky indukované $7 D003967
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a inhibitory enzymů $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D004791
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a isochinoliny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D007546
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a nehodgkinský lymfom $x farmakoterapie $x patologie $7 D008228
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a fosfatidylinositol-3-kinasy $x metabolismus $7 D019869
650    _2
$a puriny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011687
650    _2
$a rituximab $x aplikace a dávkování $7 D000069283
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Miller, Carole B $u Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
700    1_
$a Ardeshna, Kirit M $u University College London Hospitals National Health Service Foundation Trust, London, United Kingdom.
700    1_
$a Tetreault, Scott $u Florida Cancer Specialists, Tallahassee, FL.
700    1_
$a Assouline, Sarit E $u McGill University, Montreal, Quebec, Canada.
700    1_
$a Mayer, Jiri $u Fakultní Nemocnice Brno, Brno, Czech Republic.
700    1_
$a Merli, Michele $u Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
700    1_
$a Lunin, Scott D $u Florida Cancer Specialists, Tallahassee, FL.
700    1_
$a Pettitt, Andrew R $u University of Liverpool, Liverpool, United Kingdom.
700    1_
$a Nagy, Zoltan $u Semmelweis Egyetem, Budapest, Hungary.
700    1_
$a Tournilhac, Olivier $u Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, France.
700    1_
$a Abou-Nassar, Karem-Etienne $u Centre intégré de santé et de services sociaux de l'Outaouais, Gatineau, Quebec, Canada.
700    1_
$a Crump, Michael $u Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
700    1_
$a Jacobsen, Eric D $u Dana-Farber Cancer Institute, Boston, MA.
700    1_
$a de Vos, Sven $u Ronald Reagan University of California, Los Angeles, Medical Center, Los Angeles, CA.
700    1_
$a Kelly, Virginia M $u Infinity Pharmaceuticals, Cambridge, MA.
700    1_
$a Shi, Weiliang $u Infinity Pharmaceuticals, Cambridge, MA.
700    1_
$a Steelman, Lori $u Infinity Pharmaceuticals, Cambridge, MA.
700    1_
$a Le, NgocDiep $u Verastem Oncology, Needham, MA.
700    1_
$a Weaver, David T $u Verastem Oncology, Needham, MA.
700    1_
$a Lustgarten, Stephanie $u Verastem Oncology, Needham, MA.
700    1_
$a Wagner-Johnston, Nina D $u Washington University in St Louis, St Louis, MO.
700    1_
$a Zinzani, Pier Luigi, $d 1959- $u University of Bologna, Bologna, Italy. $7 xx0314852
773    0_
$w MED00002596 $t Journal of clinical oncology $x 0732-183X $g Roč. 37, č. 11 (2019), s. 912-922
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30742566 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20240313110204 $b ABA008
999    __
$a ok $b bmc $g 1525460 $s 1096658
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 37 $c 11 $d 912-922 $e 20190211 $i 0732-183X $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace